title: [Renal cell carcinoma: what is new in 2010?].
abstract: This overview presents new insights into renal cell carcinoma (RCC). The search for new target structures for targeted therapy as well as diagnostic and prognostic markers continues to remain a desirable area of research. Investigations are focusing on the use of well-established and new therapeutic agents for metastatic RCC and an increasingly liberal indication for organ-sparing surgery for renal tumors. The response to systemic treatment in metastatic RCC is also being evaluated in defined subpopulations.
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinik, Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, Frankfurt am Main, Germany. Igor.Tsaur@kgu.de
authors.forename: I
authors.initials: I
authors.lastname: Tsaur
authors.forename: A
authors.initials: A
authors.lastname: Haferkamp
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D006801:Humans; D007677:Kidney Function Tests; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods; D059351:Organ Sparing Treatments; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases